NEW YORK (GenomeWeb News) – Imaging company Definiens and the cancer treatment technology company Clarient have agreed to co-develop tools for evaluating cancer biomarkers, Clarient said today.
 
Under the terms of the five-year agreement, the companies will develop a series of image analysis tools that Clarient will use in its internal research programs and will also offer through its PathSite customer web portal.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.